Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs AZD-1775 (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 15 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 15 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 22 May 2015 New trial record